Terms: = Lung cancer AND SET, I2PP2A, 6418, ENSG00000119335, TAF-IBETA, PHAPII, IGAAD, 2PP2A AND Treatment
2296 results:
1. The efficiency and safety of temozolomide and PD-1/L1 inhibitors in pretreated NSCLC with brain metastasis: a retrospective cohort.
Li X; Wu D; Tang J; Wu Y
J Cancer Res Clin Oncol; 2024 May; 150(5):271. PubMed ID: 38780840
[TBL] [Abstract] [Full Text] [Related]
2. Development and validation of a model for predicting upstage in minimally invasive lung adenocarcinoma in Chinese people.
Liao Y; Li Z; Song L; Xue Y; Chen X; Feng G
World J Surg Oncol; 2024 May; 22(1):135. PubMed ID: 38778366
[TBL] [Abstract] [Full Text] [Related]
3. Survival Predictive Nomograms for Non-Surgical Brain Metastases Patients From Non-Small Cell lung cancer Receiving Radiotherapy: A Population-Based Study.
Li P; Luo J; Zheng Z; Meng L; Zhang A; Cao W; Gong X
Cancer Control; 2024; 31():10732748241255212. PubMed ID: 38769789
[TBL] [Abstract] [Full Text] [Related]
4. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
Dang J; Xu G; Guo G; Zhang H; Shang L
J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
[TBL] [Abstract] [Full Text] [Related]
5. Bioinformatics analysis and validation of mesenchymal stem cells related gene MT1G in osteosarcoma.
Zheng S; Cheng X; Ke S; Zhang L; Wu H; He D; Cheng X
Aging (Albany NY); 2024 May; 16(9):8155-8170. PubMed ID: 38747739
[TBL] [Abstract] [Full Text] [Related]
6. Prediction of Prognostic Features Based on Neutrophil-Related Genes for lung Squamous Cell Carcinoma Reveals Immune Landscape and Drug Candidates.
Sili D; Nan Z
Rev Invest Clin; 2024; 76(2):116-131. PubMed ID: 38740381
[TBL] [Abstract] [Full Text] [Related]
7. Engineering PD-1-targeted small protein variants for in vitro diagnostics and in vivo PET imaging.
Mierzwicka JM; Petroková H; Kafková LR; Kosztyu P; Černý J; Kuchař M; Petřík M; Bendová K; Krasulová K; Groza Y; Vaňková L; Bharadwaj S; Panova N; Křupka M; Škarda J; Raška M; Malý P
J Transl Med; 2024 May; 22(1):426. PubMed ID: 38711085
[TBL] [Abstract] [Full Text] [Related]
8. Gefitinib metabolism-related lncRNAs for the prediction of prognosis, tumor microenvironment and drug sensitivity in lung adenocarcinoma.
Guo Z; Zhang X; Yang D; Hu Z; Wu J; Zhou W; Wu S; Zhang W
Sci Rep; 2024 May; 14(1):10348. PubMed ID: 38710798
[TBL] [Abstract] [Full Text] [Related]
9. Significance of
Lin H; Wang J; Shi Q; Wu M
PeerJ; 2024; 12():e17338. PubMed ID: 38708353
[TBL] [Abstract] [Full Text] [Related]
10. A vascularized breast cancer spheroid platform for the ranked evaluation of tumor microenvironment-targeted drugs by light sheet fluorescence microscopy.
Ascheid D; Baumann M; Pinnecker J; Friedrich M; Szi-Marton D; Medved C; Bundalo M; Ortmann V; Öztürk A; Nandigama R; Hemmen K; Ergün S; Zernecke A; Hirth M; Heinze KG; Henke E
Nat Commun; 2024 Apr; 15(1):3599. PubMed ID: 38678014
[TBL] [Abstract] [Full Text] [Related]
11. Prediction of Responsiveness to PD-L1/PD-1 Inhibitors Using miRNA Profiles Associated With PD-L1 Expression in lung Adenocarcinoma and Squamous Cell Carcinoma.
Koh YW; Han JH; Haam S; Lee HW
Anticancer Res; 2024 May; 44(5):2081-2089. PubMed ID: 38677736
[TBL] [Abstract] [Full Text] [Related]
12. 5-Hydroxymethylcytosine in Cell-Free DNA Predicts Immunotherapy Response in lung cancer.
Shao J; Xu Y; Olsen RJ; Kasparian S; Sun K; Mathur S; Zhang J; He C; Chen SH; Bernicker EH; Li Z
Cells; 2024 Apr; 13(8):. PubMed ID: 38667328
[TBL] [Abstract] [Full Text] [Related]
13. Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer.
Zheng L; Hu F; Huang L; Lu J; Yang X; Xu J; Wang S; Shen Y; Zhong R; Chu T; Zhang W; Li Y; Zheng X; Han B; Zhong H; Nie W; Zhang X
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38641349
[TBL] [Abstract] [Full Text] [Related]
14. TIMM17A overexpression in lung adenocarcinoma and its association with prognosis.
Miao L; Wu D; Zhao H; Xie A
Sci Rep; 2024 Apr; 14(1):8840. PubMed ID: 38632467
[TBL] [Abstract] [Full Text] [Related]
15. The prognostic value of sialylation-related long non-coding RNAs in lung adenocarcinoma.
Wang B; Hou C; Yu X; Liu J; Wang J
Sci Rep; 2024 Apr; 14(1):8879. PubMed ID: 38632255
[TBL] [Abstract] [Full Text] [Related]
16. Architecting the metabolic reprogramming survival risk framework in LUAD through single-cell landscape analysis: three-stage ensemble learning with genetic algorithm optimization.
Sun X; Nong M; Meng F; Sun X; Jiang L; Li Z; Zhang P
J Transl Med; 2024 Apr; 22(1):353. PubMed ID: 38622716
[TBL] [Abstract] [Full Text] [Related]
17. Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker lung Adenocarcinoma Patients without EGFR or ALK Alterations.
Park SJ; Ju S; Goh SH; Yoon BH; Park JL; Kim JH; Lee S; Lee SJ; Kwon Y; Lee W; Park KC; Lee GK; Park SY; Kim S; Kim SY; Han JY; Lee C
Cancer Res; 2024 May; 84(9):1491-1503. PubMed ID: 38607364
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic and onco-immunological value of immune-related eRNAs-driven genes in lung adenocarcinoma.
Wu X; Zhao X; Zhou C; Wei N; Xu Z; Zhang X
J Cancer Res Clin Oncol; 2024 Apr; 150(4):188. PubMed ID: 38602568
[TBL] [Abstract] [Full Text] [Related]
19. Network-based identification of key proteins and repositioning of drugs for non-small cell lung cancer.
Adeyemo OM; Ashimiyu-Abdusalam Z; Adewunmi M; Ayano TA; Sohaib M; Abdel-Salam R
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2031. PubMed ID: 38600056
[TBL] [Abstract] [Full Text] [Related]
20. Non-invasive prediction for pathologic complete response to neoadjuvant chemoimmunotherapy in lung cancer using CT-based deep learning: a multicenter study.
Qu W; Chen C; Cai C; Gong M; Luo Q; Song Y; Yang M; Shi M
Front Immunol; 2024; 15():1327779. PubMed ID: 38596674
[TBL] [Abstract] [Full Text] [Related]
[Next]
